Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL17241463 | 0.84 | CYP2C19 (0.40) | MEN1KMT2ATSHRCYP2C19HIF1A | |
| SCHEMBL15063824 | 0.84 | DGAT1 (0.33) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL12873376 | 0.83 | ALDH1A1 (0.32) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL4553890 | 0.80 | DGAT1 (0.37) | CYP2D6DGAT1HMGCRCHRM1TBXA2R | |
| SCHEMBL19743162 | 0.80 | MAOA (0.32) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL9877305 | 0.80 | CYP2D6 (0.32) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| Imidazole SCHEMBL20699762 | 0.79 | ALDH1A1 (0.37) | — | |
| SCHEMBL2150574 | 0.78 | TDP1 (0.32) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL21169172 | 0.76 | CYP2D6 (0.32) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL4831111 | 0.74 | CYP2D6 (0.37) | CYP2D6DGAT1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | disclosed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739694-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12617774-B2 | Substituted indole compounds and methods of use thereof | NOVARTIS AG (CH) | 2026-05-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | CYP2D6 1953/4885DGAT1 2829/4885HMGCR 3252/4885 |
| US-12617774-B2 | Substituted indole compounds and methods of use thereof | CFB, CFD, TFPI | CYP2D6 778/4885DGAT1 4676/4885HMGCR 3481/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | CYP2D6 3785/4885DGAT1 1944/4885HMGCR 3757/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP2D6 1257/4885DGAT1 2161/4885HMGCR 2102/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CYP2D6 3802/4885DGAT1 4482/4885HMGCR 4513/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | CYP2D6 92/4885DGAT1 1434/4885HMGCR 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.